Announcements Trials

Browse Landscape

Phase

Phase 4 6 Phase 2 4 Phase NA 2 Phase EARLY_PHASE1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Rosacea 1 Meibomian Gland Dysfunction 1 Chalazion 1

Interventions

Magnetic Resonance Spectroscopy 59 Cyclophosphamide 44 pembrolizumab 34 Radiotherapy 30 fludarabine 27 Nivolumab 26 Biopsy 26 Metformin 22 Fluorodeoxyglucose F18 22 Specimen Handling 20 Bevacizumab 20 Temozolomide 17 Radiosurgery 17 Cisplatin 16 Carboplatin 14 Fluorouracil 13 Dexamethasone 13 Paclitaxel 12 Gemcitabine 12 Etoposide 12 gallium 68 PSMA-11 11 durvalumab 11 X-Rays 11 Surgical Procedures, Operative 11 Radiation 11 Positron Emission Tomography Computed Tomography 11 Letrozole 11 Irinotecan 11 Ipilimumab 11 Surveys and Questionnaires 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase EARLY_PHASE1 × OTHER × Tetracycline × Clear all

NCT01763437 2017-01-12

TET

The Cleveland Clinic

Phase EARLY_PHASE1 Withdrawn

Meibomian Gland Dysfunction, Rosacea, Chalazion

Data powered by HemOnc (CC BY 4.0) Colophon ⚡